Cordex files patent application for anti-arrhythmic drug

Cordex Pharma, a developer of cardiovascular medicines, has filed a formulation patent covering its lead product, ATPace.

ATPace is a stable liquid formulation of adenosine triposphate (ATP) for intravenous administration. ATPace is being developed as a therapeutic drug for the acute management of paroxysmal supraventricular tachycardia (PSVT) as well as a diagnostic test for the identification of patients with bradycardic (slow heart rate) syncope who may benefit from pacemaker therapy.

Cordex has recently announced the submission to the FDA of an amended Phase III clinical trial protocol with ATPace as an anti-arrhythmic drug for the conversion of PSVT to normal sinus rhythm. The FDA is currently reviewing this protocol through the special protocol assessment procedure.

Amir Pelleg, Cordex’s president and chief scientific officer, said: We are very pleased with the unmatched stability of our proprietary formulation, which is over four years. It ensures a reliable product that maintains its pharmacologic profile throughout its shelf life. This patent application will add additional coverage to that afforded by existing patents and other pending patent applications.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). Cordex has a portfolio of investigational medicines, of which two are in late stages of clinical development.